Pharmacodynamics of the 1R cis -1'R cis isomer of atracurium (51W89) in health and chronic renal failure

Abstract
We have studied the pharmacodynamics of the 1R cis-1′R cis isomer of atracurium (51W89) in 15 healthy subjects and in 17 patients with chronic renal failure using a bolus dose of 51W89 0.1 mg kg−1 (2 × ED95 Fifteen patients with normal renal function were investigated also using an approximately equipotent dose of atracurium (0.4 mg kg−1. The compound surface action potential of the adductor pollicis muscle, in response to train-of-four stimulation of the ulnar nerve at the wrist, was recorded until recovery of the height of the first response of the train-of-four compared with baseline (T1:T0) had reached at least 85% and the train-of-four ratio (T4:T1) at least 80%. In the healthy and renal failure patients who received 51W89, there were no significant differences in any of the onset or recovery variables except for the time to 90% depression of T1:T0, which was longer in patients with renal failure (mean 3.7 min vs 2.4 min; P < 0.05). Of the healthy patients who were given either 51W89 or atracurium, there were no significant differences in the onset data, except for time to maximum block, which was longer in the 51W89 group (mean 7.7 min vs 6.2 min; P 0.01). The mean times to 10%, 25%, 50% and 75% recovery of T1:T0 and the time for T4:T1 > 70% were significantly longer in patients receiving 51W89. We conclude that 51W89 has an intermediate duration of action which was not significantly affected by the presence of chronic renal failure. In healthy patients, recovery from 51W89 may take slightly longer than that after atracurium.

This publication has 0 references indexed in Scilit: